Fosifloxuridine nafalbenamide is under clinical development by NuCana and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Fosifloxuridine nafalbenamide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Fosifloxuridine nafalbenamide overview
Fosifloxuridine nafalbenamide (NUC-3373) is under development for the treatment of advanced solid tumors including colorectal cancer, breast cancer, cholangiocarcinoma, pleural mesothelioma, basal cell carcinoma, non-small cell lung cancer. The drug candidate consists of the active anti-cancer metabolite, FUDR-MP and a protective phosphoramidate moiety. It is a small molecule administered intravenously. The drug candidate is developed based on Protide technology platform.
NuCana, formerly NuCana BioMed, is a clinical-stage biopharmaceutical company. It focuses on developing novel and transformational medicines for cancer treatments. Its key products include Acelarin, which is in phase III clinical studies, and used to treat biliary tract cancer. The company is also developing products such as NUC-3373 and NUC-7738, which are under Phase I study and used to treat solid tumors. NuCana develops products based on the ProTide technology platform, which focuses on developing new generation, anti-cancer agents. The company markets its products in the UK and the US. NuCana is headquartered in Edinburgh, the UK.
For a complete picture of Fosifloxuridine nafalbenamide’s drug-specific PTSR and LoA scores, buy the report here.